Abstract
Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autologous stem cell transplantation also showed activity in RRMM. Dual- target CAR T cells are in clinical trials for RRMM. This review summarized the recent updates of ongoing CAR T clinical trials for multiple myeloma.
Keywords:
B cell maturation antigen; BCMA; CAR T; Chimeric antigen receptor; Multiple myeloma.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antigens, CD19 / immunology
-
Antigens, Neoplasm / immunology
-
B-Cell Maturation Antigen / antagonists & inhibitors
-
B-Cell Maturation Antigen / immunology
-
B-Cell Maturation Antigen / metabolism
-
Clinical Trials as Topic
-
Combined Modality Therapy / methods
-
Humans
-
Immunotherapy, Adoptive* / methods
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / immunology*
-
Multiple Myeloma / therapy*
-
Receptors, Antigen, T-Cell / genetics
-
Receptors, Antigen, T-Cell / metabolism*
-
Receptors, Chimeric Antigen / genetics
-
Receptors, Chimeric Antigen / metabolism*
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / metabolism*
Substances
-
Antigens, CD19
-
Antigens, Neoplasm
-
B-Cell Maturation Antigen
-
CD19 molecule, human
-
Receptors, Antigen, T-Cell
-
Receptors, Chimeric Antigen